Lumacaftor (VX-809) | CFTR Modulator

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	936727-05-8
Formula :	C₂₄H₁₈F₂N₂O₅
M.W :	452.41
SMILES Code :	O=C(O)C1=CC=CC(C2=NC(NC(C3(C4=CC=C(OC(F)(F)O5)C5=C4)CC3)=O)=CC=C2C)=C1
Synonyms :	VX-809; VRT 826809; Orkambi
MDL No. :	MFCD16659051
InChI Key :	UFSKUSARDNFIRC-UHFFFAOYSA-N
Pubchem ID :	16678941

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Human monocytes	5 μM	1 h	Lumacaftor/ivacaftor treatment restored the calcium response to thapsigargin in CF monocytes, suggesting that Lumacaftor/ivacaftor may reduce the overexpression of MMP9 in CF patients by modulating calcium homeostasis.	PMC7048645
Human Bronchial Epithelial Cells (HBE)	3 μM	24 h	To evaluate the efficacy of Lumacaftor on F508del and other CFTR mutants, results showed that A561E/A561E and F508del/F508del cells responded significantly to Lumacaftor, while N1303K/G542X cells showed no significant response.	PMC4484512
Fischer rat thyroid (FRT) cells	3 μM	24 h	To evaluate the effect of Lumacaftor on P67L CFTR protein expression, results showed that Lumacaftor significantly increased the expression of the mature, fully glycosylated form (band C) of P67L CFTR, reaching levels comparable to those of wild-type CFTR.	PMC5029786
Calu-3 2B4 cells	50 µM	48 h	To test the effect of CFTR modulators on SARS-CoV-2 replication, results showed that Lumacaftor significantly reduced viral titers.	PMC9973274

Mice	Wild-type mice (C57BL/6N)	Intraperitoneal injection	3 mg/kg	Twice daily for 2 days	Lumacaftor pretreatment abolishes the circadian rhythm in cerebrovascular myogenic reactivity and eliminates the time-of-day difference in SAH-induced neurological injury.	PMC8700310
mice	K18-hACE2 mice	intraperitoneal injection	12 mg/kg	once daily until 8 days post-infection	To test the protective effect of CFTR modulators in SARS-CoV-2-infected mice, results showed that Lumacaftor significantly improved survival rates.	PMC9973274
Mice	Colorectal cancer model	Intraperitoneal injection	30 mg/kg	Every 2 days until sacrificed	Combination of Lumacaftor with anti-PD-1 antibody inhibits CRC growth and enhances anti-tumor immunity	PMC11239938

{[proInfo.proName]}

CAS No.: 936727-05-8

{[proInfo.proName]}

CAS No.: 936727-05-8

Alternative Products

Product Details of Lumacaftor

Safety of Lumacaftor

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03474042	Cystic Fibrosis	Phase 2	Completed	-	Germany ... More >> Study Site II Berlin, Germany Study Site X Dresden, Germany Study Site III Essen, Germany Study Site IV Frankfurt, Germany Study Site I Heidelberg, Germany Study Site V Köln, Germany Study Site VI München, Germany Study Site IX Stuttgart, Germany Study Site VIII Tübingen, Germany Less <<
NCT02821130	-		Active, not recruiting	December 2019	Canada, British Columbia ... More >> UBC James Hogg Research Centre, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z1Y6 Less <<
NCT02965326	Cystic Fibrosis	Not Applicable	Recruiting	October 2020	France ... More >> Necker Hospital Recruiting Paris, France, 75014 Contact: SERMET Isabelle, Professor 01 44 49 48 87 isabelle.sermet@nck.aphp.fr Principal Investigator: SERMET Isabelle, Professor Less <<
NCT02275936	Cystic Fibrosis	Phase 1	Completed	-	United States, Alabama ... More >> University of Alabama @ Birmingham Birmingham, Alabama, United States, 35294 United States, California Stanford University Palo Alto, California, United States, 94304 United States, Colorado Children's CO Aurora, Colorado, United States, 80045 National Jewish Health Denver, Colorado, United States, 80206 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Iowa University of Iowa Children's Hospital Iowa City, Iowa, United States, 52242 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Massachusetts Boston Children's Hospital Boston, Massachusetts, United States, 02115 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington University St. Louis, Missouri, United States, 63110 United States, New York Columbia University New York, New York, United States, 10032 The New York Presbyterian Hospital, Columbia University Medical Center New York, New York, United States, 10032 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Cincinnati Children's Hospital Cincinnati, Ohio, United States, 45229 Rainbow Babies and Children's Hospital - Case Medical Center Cleveland, Ohio, United States, 44106 Nationwide Children's Hospital Columbus, Ohio, United States, 43205 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Less <<
NCT02310789	-		Completed	-	-
NCT03140527	Healthy Volunteer - Complete ... More >> Cystic Fibrosis Less <<	Phase 1	Recruiting	August 2018	-
NCT02709109	Cystic Fibrosis	Phase 2	Completed	-	-
NCT02310789	Cystic Fibrosis	Not Applicable	Completed	-	United States, California ... More >> Stanford Hospital and Clinics Stanford, California, United States, 94305 Less <<
NCT03445793	-		Recruiting	December 31, 2019	United States, Colorado ... More >> National Jewish Heatlh Recruiting Denver, Colorado, United States, 80206 Contact: Terri Herrud, BS 303-398-1453 herrudt@njhealth.org Less <<
NCT02589236	Cystic Fibrosis	Phase 2	Completed	-	-
NCT03061331	Cystic Fibrosis	Phase 2	Completed	-	Netherlands ... More >> HagaZiekenhuis Den Haag, Netherlands University Medical Center, Utrecht, Department of Pulmonology and Tuberculosis Heidelberglaan, Netherlands Less <<
NCT03150719	Cystic Fibrosis	Phase 3	Completed	-	-
NCT03061331	-		Completed	-	-
NCT03125395	Cystic Fibrosis	Phase 3	Active, not recruiting	July 26, 2019	-
NCT03506061	Cystic Fibrosis	Phase 2	Not yet recruiting	May 2023	United States, Alabama ... More >> University of Alabama Cystic Fibrosis Research Center Not yet recruiting Birmingham, Alabama, United States, 35233 Contact: George Soloman, MD 205-975-9776 msolomon@uab.edu United States, Georgia Emory Children's Center Not yet recruiting Atlanta, Georgia, United States, 30322 Contact: Eric Sorscher, MD 205-612-1327 esorscher@emory.edu Less <<
NCT02875366	Cystic Fibrosis	Phase 4	Completed	-	Australia, Victoria ... More >> Melbourne, Victoria, Australia Parkville, Victoria, Australia Australia Adelaide, Australia Camperdown, Australia Clayton, Australia Nedlands, Australia New Lambton Heights, Australia Randwick, Australia South Brisbane, Australia Subiaco, Australia Westmead, Australia United Kingdom Edinburgh, United Kingdom Less <<
NCT03625466	Cystic Fibrosis	Phase 2	Recruiting	May 2021	Germany ... More >> Charite Paediatric Pulmonology Department Recruiting Berlin, Germany Justus-Leibig-Universitat Zentrum fur Kinderheilkunde und Jugendmedizin Recruiting Giessen, Germany Hannover Medical School Recruiting Hannover, Germany Heidelberg Cystic Fibrosis Center Recruiting Heidelberg, Germany Universitatsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin Recruiting Lubeck, Germany Less <<
NCT01931839	Cystic Fibrosis, Homozygous or... More >> Heterozygous for the F508del-CFTR Mutation Less <<	Phase 3	Completed	-	-
NCT01888393	Hepatic Impairment ... More >> Healthy Less <<	Phase 1	Completed	-	Czech Republic ... More >> Praha, Czech Republic Slovakia Bratislava, Slovakia Less <<
NCT03565692	-		Not yet recruiting	March 1, 2020	France ... More >> CHU de Bordeaux - CRCM Not yet recruiting Bordeaux, France, 33000 Contact: Mickael FAYON, MD,PhD mickael.fayon@chu-bordeaux.fr Principal Investigator: Mickael FAYON, MD,PhD Sub-Investigator: Patrick BERGER, MD,PhD Sub-Investigator: Raphael ENAUD, MD Centre Hospitalier Universitaire Grenoble Alpes Not yet recruiting Grenoble, France, 38000 Contact: Catherine Llerena, MD CLlerena@chu-grenoble.fr Principal Investigator: Catherine Llerena, MD Sub-Investigator: Boubou Camara, MD CHRU de Lille Not yet recruiting Lille, France, 69000 Contact: Nathalie Wizla, MD nathalie.wizla@chru-lille.fr Principal Investigator: Nathalie Wizla, MD Sub-Investigator: Anne Prévotat, MD Hospices Civils de Lyon Not yet recruiting Lyon, France, 69000 Contact: Philippe Reix, MD philippe.reix@chu-lyon.fr Principal Investigator: Philippe Reix, MD Assistance publique Hôpitaux Marseille Not yet recruiting Marseille, France, 13000 Contact: Jean Christophe Dubus, MD,PhD JeanChristophe.DUBUS@ap-hm.fr Principal Investigator: Jean Christophe Dubus, MD,PhD Assistance Publique Hôpitaux de paris Not yet recruiting Paris, France, 75000 Contact: Harriet Corvol, MD,PhD harriet.corvol@aphp.fr Principal Investigator: Harriet Corvol, MD,PhD Sub-Investigator: Pierre-Regis BURGEL, MD Sub-Investigator: Isabelle Sermet-Gaudelus, MD,PhD Sub-Investigator: Michèle Gérardin Gérardin, MD Hôpital FOCH Not yet recruiting Suresnes, France, 92150 Contact: Dominique Grenet, MD d.grenet@hopital-foch.org Principal Investigator: Dominique Grenet, MD CHU de Toulouse Not yet recruiting Toulouse, France, 31000 Contact: Marlène Murris-Espin, MD murris.m@chu-toulouse.fr Contact: Murris-Espin Principal Investigator: Marlène Murris-Espin, MD Less <<
NCT02823470	Cystic Fibrosis	Phase 4	Terminated(Study terminated ea... More >>rly due to slow recruitment of patients.) Less <<	-	United States, Connecticut ... More >> Hartford, Connecticut, United States United States, District of Columbia Washington, District of Columbia, United States United States, Florida Orlando, Florida, United States United States, Georgia Atlanta, Georgia, United States United States, Mississippi Jackson, Mississippi, United States United States, New Mexico Albuquerque, New Mexico, United States United States, South Carolina Columbia, South Carolina, United States Canada, Alberta Edmonton, Alberta, Canada Canada, British Columbia Victoria, British Columbia, Canada Canada, New Brunswick Saint John, New Brunswick, Canada Canada Quebec, Canada Less <<
NCT02797132	Cystic Fibrosis	Phase 3	Completed	-	-
NCT02544451	Cystic Fibrosis	Phase 3	Active, not recruiting	November 2019	-
NCT01931839	-		Completed	-	-
NCT02823470	-		Terminated(Study terminated ea... More >>rly due to slow recruitment of patients.) Less <<	-	-
NCT01910415	Cystic Fibrosis	Phase 1	Completed	-	Netherlands ... More >> Zuidlaren, Netherlands Less <<
NCT03601637	Cystic Fibrosis	Phase 3	Recruiting	September 2020	United States, Alabama ... More >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35294 United States, Arkansas Arkansas Children's Hospital Recruiting Little Rock, Arkansas, United States, 72202 United States, Illinois Ann & Robert Lurie Children's Hospital of Chicago Recruiting Chicago, Illinois, United States, 60611 United States, Indiana Riley Hospital for Children at Indiana University Health Recruiting Indianapolis, Indiana, United States, 46202 United States, Massachusetts Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 United States, Minnesota Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota Recruiting Minneapolis, Minnesota, United States, 55404 United States, Missouri The Children's Mercy Hospital Recruiting Kansas City, Missouri, United States, 64108 United States, New York Albany Medical College Recruiting Albany, New York, United States, 12208 United States, Pennsylvania Children's Hospital of Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19104 United States, Texas Cook Children's Medical Center Recruiting Fort Worth, Texas, United States, 76104 United States, Utah University of Utah / Primary Children's Medical Center Recruiting Salt Lake City, Utah, United States, 84132 United States, Washington Seattle Children's Hospital Recruiting Seattle, Washington, United States, 98105 United States, Wisconsin University of Wisconsin Hospital and Clinics Recruiting Madison, Wisconsin, United States, 53792 Canada British Columbia's Children's Hospital Recruiting Vancouver, Canada Less <<
NCT01807949	Cystic Fibrosis, Homozygous fo... More >>r the F508del CFTR Mutation Less <<	Phase 3	Completed	-	-
NCT02858843	Cystic Fibrosis ... More >> Diabetes Less <<	Not Applicable	Terminated(We were unable to e... More >>nroll eligible subjects for the study.) Less <<	-	-
NCT01807923	Cystic Fibrosis, Homozygous fo... More >>r the F508del CFTR Mutation Less <<	Phase 3	Completed	-	-
NCT02797132	-		Completed	-	-
NCT02514473	Cystic Fibrosis	Phase 3	Completed	-	-
NCT03512119	-		Recruiting	October 10, 2018	France ... More >> Hôpitaux Universitaires de Strasbourg Recruiting Strasbourg, Alsace, France, 67000 Contact: Laurence KESSLER Principal Investigator: Laurence KESSLER, MD Centre Hospitalier Universitaire d'Angers Recruiting Angers, France, 49033 Contact: Françoise TROUSSIER Principal Investigator: Françoise TROUSSIER Hôpital Renée Sabran Recruiting Giens, France, 83406 Contact: Laurent MELY Principal Investigator: Laurent MELY Centre Hospitalier Lyon Sud Recruiting Lyon, France, 69000 Contact: Isabelle DURIEU Principal Investigator: Isabelle DURIEU Hôpital NORD - Assistance Publique Hôpitaux de Marseille Recruiting Marseille, France, 13385 Contact: Bérengère COLTEY Principal Investigator: Bérengère COLTEY Hôpital Arnaud de Villeneuve Recruiting Montpellier, France, 34295 Contact: Raphael CHIRON Principal Investigator: Raphael CHIRON Hôpital Robert Debré Recruiting Paris, France, 75019 Contact: Michèle GERARDIN Principal Investigator: Michèle GERARDIN American Memorial Hospital Recruiting Reims, France, 51092 Contact: Michel ABLEY Principal Investigator: Michel ABELY Clinique "Mucoviscidose" Presqu'île de Perharidy Recruiting Roscoff, France, 29684 Contact: Gilles RAULT Principal Investigator: Gilles RAULT Hôpital Charles Nicolle Recruiting Rouen, France, 76031 Contact: Stéphane DOMINIQUE Principal Investigator: Stéphane DOMINIQUE Hôpital FOCH Recruiting Suresnes, France, 92151 Contact: Florence BOUILLOUD Principal Investigator: Florence BOUILLOUD Hôpital Bretonneau - CHRU de Tours Recruiting Tours, France, 37044 Contact: Julie MANKIKIAN Principal Investigator: Julie MANKIKIAN Hôpital de Clocheville - CHRU de Tours Recruiting Tours, France, 37044 Contact: Laure COSSON Principal Investigator: Laure COSSON Less <<
NCT01807949	-		Completed	-	-
NCT03475381	-		Active, not recruiting	June 30, 2018	France ... More >> Adult CF center, Service de Pneumologie, Cochin Hospital Paris, France, 75006 Less <<
NCT02390219	Cystic Fibrosis ... More >> Advanced Lung Disease Less <<	Phase 3	Completed	-	United States, Colorado ... More >> Denver, Colorado, United States United States, Florida Tampa, Florida, United States United States, Illinois Chicago, Illinois, United States United States, Missouri Saint Louis, Missouri, United States United States, Pennsylvania Pittsburgh, Pennsylvania, United States United States, Texas Houston, Texas, United States Less <<
NCT01768663	Cystic Fibrosis	Phase 1	Completed	-	United States, Indiana ... More >> Evansville, Indiana, United States Less <<
NCT02390219	-		Completed	-	-
NCT01807923	-		Completed	-	-
NCT02514473	-		Completed	-	-
NCT01225211	Cystic Fibrosis	Phase 2	Completed	-	-
NCT01899105	Cystic Fibrosis	Phase 1	Completed	-	United States, Florida ... More >> Daytona, Florida, United States Less <<
NCT02653027	Diabetes Cyst... More >>ic Fibrosis Less <<	Not Applicable	Withdrawn(We couldn't find any... More >> eligible subjects for the study because most of the study population had already started on the combination therapy.) Less <<	-	-
NCT01897233	Cystic Fibrosis	Phase 3	Completed	-	-
NCT02807415	-		Recruiting	June 2019	Germany ... More >> Justus-Liebig-University Recruiting Gießen, Germany, 35385 Contact: Lutz Nährlich, MD 004964198557620 lutz.naehrlich@paediat.med.uni-giessen.de Contact: Claudia Rückes-Nilges, Dipl-Biol 004964198556945 claudia.rueckes-nilges@paediat.med.uni-giessen.de Principal Investigator: Lutz Nährlich, MD Sub-Investigator: Stefan Kuhnert, MD Hannover Medical School Recruiting Hannover, Germany, 30625 Contact: Burkhard Tümmler, MD PhD 00495115322920 tuemmler.burkhard@mh-hannover.de Contact: Christian Dopfer, MD 00495115326111 dopfer.christian@mh-hannover.de Principal Investigator: Burkhard Tümmler, MD PhD Sub-Investigator: Christian Dopfer, MD University of Heidelberg Recruiting Heidelberg, Germany, 69120 Contact: Marcus Mall, MD 00496221564502 Marcus.Mall@med.uni-heidelberg.de Contact: Simon Gräber, MD 004962215638926 Simon.Graeber@med.uni-heidelberg.de Principal Investigator: Marcus Mall, MD Sub-Investigator: Simon Gräber, MD Sub-Investigator: Susanne Dittrich, MD Less <<
NCT00865904	Cystic Fibrosis	Phase 2	Completed	-	-
NCT01897233	-		Completed	-	-
NCT01216046	Cystic Fibrosis	Phase 1	Completed	-	United States, Kansas ... More >> PRA Lenexa, Kansas, United States, 66219 Less <<
NCT01225211	-		Completed	-	-
NCT00865904	-		Completed	-	-
NCT00966602	Cystic Fibrosis	Phase 1	Completed	-	Netherlands ... More >> Zuidlaren, Netherlands Less <<
NCT03956589	Cystic Fibrosis	PHASE4	TERMINATED	2020-04-01	Antwerp University Hospital, E... More >>degem, 2650, Belgium Less <<
NCT03795363	Cystic Fibrosis		COMPLETED	2021-06-16	Children's Hospital of Philade... More >>lphia, Philadelphia, Pennsylvania, 19146, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.21mL 0.44mL 0.22mL	11.05mL 2.21mL 1.11mL	22.10mL 4.42mL 2.21mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed